MAGE-A1

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024

The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.

Key Points: 
  • The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
  • With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
  • Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
  • The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Retrieved on: 
Thursday, January 4, 2024

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.

Key Points: 
  • Additionally, we submitted INDs for two additional TCRs in December and the 30-day review period with the FDA is ongoing.
  • Plans to complete Phase 1 dosing and report clinical and translational data in 2024, and two-year relapse data in 2025.
  • Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
  • Plans to continue to build ImmunoBank with additional IND filings throughout 2024.

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Key Points: 
  • “Solid tumors are notoriously heterogenous, which may contribute to low response rates and limited duration of response following treatment with single-targeting TCR-T cell therapy.
  • TScan’s solid tumor program is designed to deliver multiplexed, enhanced TCR-T cell therapy to effectively address both target heterogeneity and HLA loss,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • “TScan has initiated a screening protocol to test for target expression and the presence of HLA genes in patients’ tumors.
  • Using TargetScan, TScan has identified a novel B*07:02-restricted epitope in the cancer/testis antigen MAGE-C2 as a promising target for TCR-T therapy.

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

Retrieved on: 
Tuesday, August 29, 2023

In addition to being expressed in ~90% of melanomas, PRAME is also frequently expressed in various other solid tumors, including ~90% of head & neck cancers and ~50% of non-small cell lung cancers.

Key Points: 
  • In addition to being expressed in ~90% of melanomas, PRAME is also frequently expressed in various other solid tumors, including ~90% of head & neck cancers and ~50% of non-small cell lung cancers.
  • All four TCR-T cell products are designed to be used in combination with each other and are being developed under a single master clinical trial protocol.
  • Patients are administered specific combinations of TCR-T cell agents based on which targets and HLAs are expressed in their tumors.
  • PRAME is a particularly important target, as it is very frequently expressed in solid tumors and recent clinical trials targeting PRAME have shown promising results.

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023

WALTHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Key Points: 
  • Revenue for the second quarter ended June 30, 2023, was $3.1 million, compared to $4.1 million for the second quarter ended June 30, 2022 (2022 Quarter).
  • Research and development expenses for the second quarter ended June 30, 2023, were $21.2 million, compared to $14.5 million for the 2022 Quarter.
  • General and administrative expenses for the second quarter ended June 30, 2023, were $6.5 million, compared to $4.8 million for the 2022 Quarter.
  • For the second quarter ended June 30, 2023, TScan Therapeutics reported a net loss of $24.0 million, compared to a net loss of $15.1 million for the 2022 Quarter.

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

Retrieved on: 
Tuesday, June 6, 2023

TSC-200-A0201 is the third TCR cleared for clinical development in the Company’s ImmunoBank following TSC-204-A0201 and TSC-204-C0702, which target MAGE-A1 presented on HLA types A*02:01 and C*07:02, respectively.

Key Points: 
  • TSC-200-A0201 is the third TCR cleared for clinical development in the Company’s ImmunoBank following TSC-204-A0201 and TSC-204-C0702, which target MAGE-A1 presented on HLA types A*02:01 and C*07:02, respectively.
  • T-Plex serves as the primary IND for TScan’s solid tumor program, enabling customized combinations of enhanced TCR-Ts to be administered to patients based on the targets and HLAs expressed in their tumors.
  • TSC-200-A0201 targets HPV16, which is an oncogenic virus that is responsible for approximately 57% of cervical cancers and approximately 21% of head and neck squamous cell carcinomas.
  • This IND clearance is further validation of the strength of our discovery platform to identify therapeutic TCRs suitable for clinical development.

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

Retrieved on: 
Thursday, June 1, 2023

“These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.

Key Points: 
  • “These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.
  • “Specifically, leveraging our MyT platform, we isolated TK 8001, a naturally optimized high-affinity TCR specific for the cancer testis antigen MAGE-A1.
  • TK-8001, has repeatedly demonstrated superior in vitro anti-tumor activity against cancer cell lines derived from a wide range of tumors and superior in vivo anti-tumor activity in a very challenging syngeneic tumor mouse model.”
    MAGE-A1-specific TCRs were isolated from MyT platform mice immunized with the MAGE-A1 epitope.
  • Human donor-derived TCRs reactive to the same epitope were synthesized based on publicly available sequences, including a clinical-stage TCR.

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

Retrieved on: 
Wednesday, March 8, 2023

WALTHAM, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted upcoming anticipated milestones.

Key Points: 
  • For the three months ended December 31, 2022, TScan Therapeutics reported a net loss of $18.7 million, compared to a net loss of $14.2 million for the 2021 Quarter.
  • As of December 31, 2022, TScan Therapeutics had cash and cash equivalents of $120.0 million excluding $5.0 million of restricted cash.
  • General and administrative expenses for the year ended December 31, 2022, were $20.4 million, compared to $13.8 million for the 2021 Period.
  • For the year ended December 31, 2022, TScan Therapeutics reported a net loss of $66.2 million, compared to a net loss of $48.6 million for the 2021 Period.

T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, February 8, 2023

SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has appointed Behzad Kharabi Masouleh, M.D., as Chief Medical Officer.

Key Points: 
  • SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has appointed Behzad Kharabi Masouleh, M.D., as Chief Medical Officer.
  • “It is with great pleasure that I welcome Behzad to the T-knife executive team,” stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • Prior to his role at Gilead, Dr. Kharabi served as global clinical lead for bi-specific antibodies in multiple myeloma at Janssen Pharmaceuticals.
  • Prof. Leo added, “Behzad has extensive clinical development experience in oncology-focused cell therapy, with a demonstrated track-record of multiple IND filings and BLA approvals.

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

Retrieved on: 
Monday, January 23, 2023

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.

Key Points: 
  • Each unique TCR-T will be filed as a secondary IND and will reference the primary T-Plex IND.
  • MAGE-A1 is a cancer-associated antigen overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.
  • TScan believes that TSC-204-C0702 is the first clinical program in MAGE-A1 for an HLA type other than A*02:01.
  • With the FDA clearance of T-Plex, along with two MAGE-targeting TCRs, we are now one step closer to bringing bespoke cell therapies to patients.